Abstract:Protein kinases play pivotal roles in various biological functions, influencing cell differentiation, promoting survival, and regulating the cell cycle. The disruption of protein kinase activity is intricately linked to pathways in tumor development. This manuscript explores the transformative impact of protein kinase inhibitors on cancer therapy, particularly their efficacy in cases driven by targeted mutations. Focusing on key tyrosine kinase inhibitors (TKIs) like Bcr-Abl, Epidermal Growth Factor Receptor (EGFR), and Vascular Endothelial Growth Factor Receptor (VEGFR), it targets critical kinase families in cancer progression. Clinical trial details of these TKIs offer insights into their therapeutic potentials. Learning from FDA-approved kinase inhibitors, the review dissects trends in kinase drug development since imatinib's paradigm-shifting approval in 2001. TKIs have evolved into pivotal drugs, extending beyond oncology. Ongoing clinical trials explore novel kinase targets, revealing the vast potential within the human kinome. The manuscript provides a detailed analysis of advancements until 2022, discussing the roles of specific oncogenic protein kinases in cancer development and carcinogenesis. Our exploration on PubMed for relevant and significant TKIs undergoing pre-FDA approval phase III clinical trials enriches the discussion with valuable findings. While kinase inhibitors exhibit lower toxicity than traditional chemotherapy in cancer treatment, challenges like resistance and side effects emphasize the necessity of understanding resistance mechanisms, prompting the development of novel inhibitors like osimertinib targeting specific mutant proteins. The review advocates thorough research on effective combination therapies, highlighting the future development of more selective RTKIs to optimize patient-specific cancer treatment and reduce adverse events.

Correction to Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application

Discovery of Tropomyosin Receptor Kinase Inhibitors as New Generation Anticancer Agents: A Review

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers

Targeting tropomyosin receptor kinase for cancer therapy

Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions

Research Progress on Small Molecules Inhibitors Targeting TRK Kinases.

Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation

Roles of tropomyosin-related kinases in tumorigenesis and their small molecular inhibitors

Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy

Multi-targeted Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer: an Era of Individualized Therapy.

Resistance to TRK inhibition mediated by convergent MAPK pathway activation

Pyrazolo[1,5- a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors-Synthetic Strategies and SAR Insights

Tyrosine kinase inhibitors: a clinical perspective

Design, Synthesis and Biological Activity of Bicyclic Carboxamide Derivatives As TRK Inhibitors

Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation

Current therapeutic landscape and resistance mechanisms to larotrectinib

Tropomyosin Receptor Kinase B (trkb) Signalling: Targeted Therapy in Neurogenic Tumours